
薬剤耐性が、血液がん治療のサイレントリスクでなくなる日
がん治療は今、新たなイノベーションの時代を迎えています。免疫療法、分子標的治療、細胞療法の進歩により、患者の治療アウトカムは劇的に改善しつつあります。ただし、これらの画期的な治療法のすべては、抗微生物薬という脆弱な基盤の上に成り立っています。
AMTD Group is a comprehensive financial services conglomerate, with businesses in financial services areas, including investment banking, asset management, digital financial solutions, insurance brokerage, and non-financial services areas such as real estate investment, talent training and education, innovative technology and digital economy investments. AMTD International (NYSE: HKIB; SGX: HKB), a subsidiary of AMTD Group, is among the largest independent investment banks in Asia and a leading investor in the fintech and new economy sectors. AMTD International is dual-listed on the New York Stock Exchange and Singapore Stock Exchange and features dual-class shares (DCS) listed on SGX.